The National Institute for Health and Care Excellence (NICE) has published draft guidelines backing use of EUSA Pharma’s Fotivda as a first-line treatment option for advanced renal cell carcinoma.
Read More
The European Commission has licensed EUSA Pharma’s Fotivda for the management of adult patients with advanced kidney cancer across the European Union as well as Norway and Iceland.
Read More
ViiV Healthcare has come out on top at this year’s PM Society Awards, an annual competition designed to recognise creativity, impact and innovation across pharmaceutical and healthcare advertising and communications.
Read More
